Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2025 · 10-Q
Revenue$120.00K$120.00K−27.3% vs Q3 2024 Net Income-$11.26M-$11.26MN/M vs Q3 2024 EPS Diluted-$0.17-$0.17N/M vs Q3 2024 Operating Income-$11,974,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,852,000N/M Margins · derivedOperating margin-9978.3%−2341.4 pt vs Q3 2024
Net margin-9381.7%−2196.8 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end